Forecast
The analysts' average price target is €53.50 (+30.58%). The median is €53.31 (+30.12%).
| Buy |
16 |
| Hold |
10 |
| Sell |
3 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Alkermes CCO sells 7,576 shares for $373,000 under 10b5-1 plan
Christian Todd Nichols, SVP and Chief Commercial Officer of Alkermes, sold 7,576 shares on Aug. 17, 2026 for a weighted average price of $49.23, netting about $373,000. The sale was executed under a Rule 10b5-1 trading plan adopted May 15, 2026 and reduced his direct holdings to 102,193 shares (≈0.06% ownership). The company reported strong H1 2026 revenue growth and a 12-month stock gain, and analysts remain generally positive on Alkermes. » More on finance.yahoo.com
Alkermes reports positive Phase‑2 data for narcolepsy drug Alixorexton
Alkermes published Phase‑2 data from the Vibrance‑1 study in 92 adults with narcolepsy type 1. Once‑daily doses of 4, 6 or 8 mg Alixorexton produced statistically significant improvements in excessive daytime sleepiness; all dose groups achieved mean Maintenance of Wakefulness Test values of at least 20 minutes and Epworth scores of ≤10 at week 6. In the 6‑mg group the weekly cataplexy rate fell versus placebo; the drug was generally well tolerated and no serious adverse events occurred. Based on these results, a global Phase‑3 program (Brilliance Studies) is now under way; Alixorexton has received Breakthrough Therapy and Orphan Drug status in the US for certain indications. » More on de.investing.com
Alkermes cuts interest margins for senior term loans
Alkermes has agreed an amendment to its loan agreement that reduces the interest margins on its secured senior term loans. The adjustment lowers the margin on the TLA facility by 0.75 percentage points and on the TLB facility by 0.50 percentage points; TLA has an outstanding amount of USD 745.3m (maturity Feb. 12, 2031), TLB USD 773.1m (maturity Aug. 12, 2031). After the amendment, TLA will bear interest at Term SOFR plus 1.75–2.25% or Alternate Base Rate plus 0.75–1.25% depending on net leverage, and TLB at Term SOFR plus 2.25% or Alternate Base Rate plus 1.25%. The agreement was made with several lenders, including JPMorgan Chase and BofA Securities as arrangers. » More on de.investing.com
Alkermes cuts full-year forecast despite strong Q2, stock falls premarket
Alkermes beat expectations in Q2 2026 with adjusted EPS of $0.00 and revenue of $496 million (+27% y/y), but was weighed down by a 2026 revenue forecast of $1.785 billion that missed the analyst consensus. The stock fell about 5.2% premarket to $50.00 as investors took profits after a strong rally year-to-date. Narcolepsy drug LUMRYZ contributed significantly to revenue, but integration costs and the muted outlook clouded sentiment. Piper Sandler raised its price target to $65 and reiterated “Overweight,” but that did not halt the short-term decline. » More on de.investing.com
Alkermes hits 52-week high of $55.28 after positive trial data
Alkermes’ stock climbed to a 52-week high of $55.28 and is trading near that level, with a year-to-date return of about 95%. The company reported positive Phase 2 data from the Alixorexton study VIBRANCE-2, prompting several analysts to raise price targets (Needham $54, Mizuho $65), while BofA moved to underperform on valuation concerns (target $38). The stock shows a high gross margin of 87%, but technical indicators like the RSI point to possible overbought conditions. » More on de.investing.com
Financials
In the last quarter, Alkermes had revenue of €423.88m and net profit of €14.38m
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 423.88m | 26.19% |
| Gross profit | 340.7m | 16.71% |
| Net profit | 14.38m | 79.61% |
| EBITDA | 61.31m | 33.88% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €7.1bn |
Number of shares | 168.04m |
52-week high/low | €50.73 - €24.61 |
| Dividends | No |
Beta | 0.27 |
P/E ratio | 15,445.00 |
PEG ratio | -154.67 |
P/B ratio | 4.17 |
P/S ratio | 4.44 |
Company profile
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
| Name | Alkermes |
| CEO | Blair Jackson |
| Headquarters | Dublin,
du Ireland |
| Website | |
| Sector | Materials |
| Industry | Chemicals |
| IPO | 16/07/1991 |
| Employees | 2,050 |
Deep Dive
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | ALKS |
Frankfurt | 8AK.F |
SIX | 8AK.SW |
München | 8AK.MU |